Most medications developed for the treatment of of symptoms related to functional GI disorders are oral medications. The patient-preference of medication route in this population is not clear, although the relative advantages of buccal, SL, intra-nasal, trans-dermal rectal and SQ also vary based on compound characteristics.

If pharmacology is equivalent, what route of administration do you think is preferred by patients with functional disorders of the foregut?